Atria Wealth Solutions Inc. Has $2.13 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Atria Wealth Solutions Inc. lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 8,741 shares of the medical instruments supplier’s stock after selling 204 shares during the period. Atria Wealth Solutions Inc.’s holdings in Becton, Dickinson and Company were worth $2,131,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jeppson Wealth Management LLC increased its position in shares of Becton, Dickinson and Company by 4.0% in the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 40 shares during the period. U.S. Capital Wealth Advisors LLC raised its position in shares of Becton, Dickinson and Company by 3.4% in the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock valued at $339,000 after buying an additional 43 shares in the last quarter. Value Partners Investments Inc. lifted its holdings in shares of Becton, Dickinson and Company by 5.2% during the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 43 shares during the period. Atlas Private Wealth Management boosted its position in shares of Becton, Dickinson and Company by 2.9% during the 3rd quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock worth $410,000 after acquiring an additional 45 shares in the last quarter. Finally, Dover Advisors LLC increased its stake in Becton, Dickinson and Company by 1.7% in the third quarter. Dover Advisors LLC now owns 2,702 shares of the medical instruments supplier’s stock valued at $699,000 after acquiring an additional 45 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Barclays upped their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Raymond James upped their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $233.50 on Tuesday. The company’s 50 day moving average price is $239.10 and its two-hundred day moving average price is $240.93. The firm has a market capitalization of $67.46 billion, a P/E ratio of 55.33, a P/E/G ratio of 1.91 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. During the same quarter in the previous year, the company posted $2.98 EPS. Becton, Dickinson and Company’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Insider Transactions at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.